Sign in
Active, not recruitingEarly phase 1

A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
11 people enrolled
Started
5 Jan 2024
Expected to end
5 Jan 2027
Type of study
Interventional
Treatments tested
  • 68Ga-PSMA-11 PET Scans
Record updated
3 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
  • Adults ≥ 18 years old
  • Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
  • Lesion size ≥ 1 cm (for the lesion to be biopsied)
  • ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
  • Planned to undergo biopsy/resection of brain lesion

Who cannot take part

  • Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
  • Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with severe allergy to both iodinated and gadolinium contrast
  • Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test <1 week before study

Where in United States

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, United States
  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack, United States
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United States
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United States
  • Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United States

About the trial

What the trial wants to find out

The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.

The group in the trial

  • Participants with high-grade gliomaTreatment being tested

    Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases

    Treatment: 68Ga-PSMA-11 PET Scans

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Investigator-Initiated Study to Evaluate PSMA Expression in Patients With High-Grade Gliomas or Brain Metastases With 68Ga-PSMA-11 PET
Record updated
3 December 2025